SGLT2 inhibitors, compared with GLP-1 RAs, were associated with lower risks for osteoarthritis and joint replacement surgery among patients with T2D.

The discovery that diabetes medication could potentially manage hydrocephalus occurred after Dr Magill observed significant ...

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in ...

A drug commonly used to treat type 2 diabetes may reduce excess fluid in the brains of patients with hydrocephalus, which ...

A study published in JAMA Surgery involving nearly 500,000 surgeries among U.S. veterans found that patients taking SGLT2 ...

GLP-1 receptor agonist users had a significant 39% higher risk of requiring KRT (95% CI, 1.19-1.63) compared with SGLT2 inhibitor users, Dr Chang’s team reported in the American Journal of ...

Smartphone-based home screening significantly boosts chronic kidney disease (CKD) diagnosis and follow-up care, enhancing ...

A study found that the newer generation of much more effective diabetes medications are reaching only a fraction of the ...

Bottom line of study: SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to ...

The widely used class of drugs, called SGLT2 inhibitors and sold under brand names such as Jardiance and Farxiga, have been on the market for over a decade as Type 2 diabetes medications.